他格适说明书
注射用替考拉宁说明书他格适
注射用替考拉宁说明书【药品名称】通用名：注射用替考拉宁英文名：Teicoplanin for Injection商品名：他格适汉语拼音：ZHU SHE YONG TI KAO LA NING【成份】本品主要成分及其化学名称为:替考拉宁其结构式为：分子式：A2-2,C88H97Cl2N9O33分子量：无Cas No：61036-62-2【性状】本品为类白色冻干块状粉物和粉末【适应证】本品可用于治疗各种严重的革兰阳性菌感染，包括不能用青霉素类和头孢菌素类其他抗生素者。
本品可用于不能用青霉素类及头孢菌素类抗生素治疗或用上述抗生素治疗失败的严重葡萄球菌感染，或对其他抗生素耐药的葡萄球菌感染。
已证明替考拉宁对下列感染有效:皮肤和软组织感染，泌尿道感染，呼吸道感染，骨和关节感染，败血症，心内膜炎及持续不卧床腹膜透析相关性腹膜炎。
在矫形手术具有革兰阳性菌感染的高危因素时，本品也可作预防用。
【规格】替考拉宁200mg 每包装含一小瓶200mg替考拉宁和一安瓿注射用水。
【用法和用量】本品既可以静脉注射也可以肌肉注射。
可以快速静脉注射，注射时间为3～5分钟之间，或缓慢静脉滴注，滴注时间不少于30分钟。
一般每日给药一次，但第一天可以给药两次。
对敏感菌所致感染的大多数病人，给药后48-72小时会出现疗效反应，疗程长短则依据感染的类型、严重程度和病人的临床反应而定。
心内膜炎和骨髓炎的疗程则推荐为3周或更长时间。
描述:本品每盒含有一小瓶替考拉宁和一安瓿适量注射用水。
本品每瓶稍微过量，因此，按下述方法配制溶液时，用注射器抽取全部溶液则可获得剂量为200mg或400mg的替考拉宁(基于药瓶的标示量)。
瓶中不含任何防腐剂。
配置方法1.含替考拉宁的小瓶2.含无菌注射用水的安瓿3.用注射器从安瓿中抽取全部注射用水4.轻轻向上推盖，就可取下彩色塑料瓶盖5.慢慢将全部注射用水沿瓶壁注入小瓶中，大约有0.2ml水将会留在注射器中。
6.用双手轻轻滚动小瓶直至药粉完全溶解。
注射用替考拉宁说明书
注射用替考拉宁的说明书【英文名】Teicoplanin【类别】抗生素【别名】肽可霉素，壁霉素、他格适 ,替考拉宁【外文名】Teicoplanin,Teicomycin,Targocid【药理毒理】本品为与万古霉素类似的新糖肽抗生素，其抗菌谱及抗菌活性与万古霉素相似。
对金葡菌的作用比万古霉素更强，不良反应更少。
本品对革兰阳性菌如葡萄球菌、链球菌、肠球菌和大多厌氧性阳性菌敏感。
药效学替考拉宁为一种新型糖肽类非肠道给药抗生素，具有强的杀菌活性。
可供每天一次静脉或肌肉注射。
本药抑制细胞壁合成的途径与万古霉素一样，干扰肽聚糖中新的部分的合成过程。
本药通过与肽聚糖亚单位中的氨基酰-D-丙氨酰-D-丙氨酸部分结合而起效应，这种结合将正常可被细菌细胞延长和交叉一桥酸识别的部位隐藏起来。
这种结合抑制两个方面：形成细胞壁链的亚单位的生长或延长将新链接到细胞壁的最终穿越一桥步骤。
因此，细胞壁的整合和牢固遭损坏，细胞生长停止，细胞最后死亡。
由于替考拉宁独特的作用机制，很少出现耐替考拉宁的菌株。
所以对青霉素类及头孢菌素类，大环内酯类、四环素和氯霉素，氨基糖苷类和利福平耐药的革兰氏阳性菌，仍对替考拉宁敏感。
药动学吸收：替考拉宁口服不吸收，肌注后的生物利用度为94%。
分布（血清浓度）：对人静注后其血清浓度显示出两相的分布（一相快速的分布紧接着是一相较慢的分布），其半衰期分别为0.3和3小时左右。
该相分布跟随一个缓慢的排泄，其半衰期为70-100小时。
【药动学】本品口服不吸收。
肌内注射tmax约2h。
PB约90%。
几乎全由肾脏排泄，肾功能正常成年人t1/2约45h～60h，肾功能障碍时延长，无尿患者可长达163h。
【适应证】耐青霉素、头孢菌素菌及青霉素过敏的革兰阳性菌感染。
【不良反应】可引起注射处持久的疼痛。
亦具有耳毒性。
人们对本药耐受性良好，不良反应一般轻微且短暂，很少需要中断治疗，严重不良反应罕见，已报道主要有以下不良反应：局部反应：红斑、局部疼痛、血栓性静脉炎。
呼吸科MRSA感染的经验治疗
MRSA感染HCAP/HAP/VAP临床表现和诊断
1. 何礼贤。耐药革兰阳性球菌肺炎的抗菌治疗。中华结核和呼吸杂志。2008；31（10）：723-4
MRSA经验性抗感染时机
危险因素 典型症状 影像学改变 痰涂片 本院耐药监测资料
CA-MRSA肺炎指南推荐
MRSA 肺炎( + / - PVL) : 利奈唑胺(600 mg q12h ivgtt) + 克林霉素(1. 2～1. 8 g q8h ivgtt) ±利福平(600 mg q12 h ivgtt) 其他的MRSA 深部感染,如血流感染、骨髓炎、脓 肿、心内膜炎及产PVL MRSA 所致感染: 一线用药: 万古霉素(1 g q12 h ivgtt) 或替考拉宁(400～800 mg qd ivgtt) (负荷剂量后) +庆大霉素(5～7mg/ kg qd ivgtt) 或利福平(300 mg 每日2 次口服) 、或夫西地酸 (500 mg 每日3 次口服) 。 二线用药:利奈唑胺((600 mg q12h ivgtt或口服)
MRSA检出率(%)
我院MRSA肺炎情况
MRSA感染的危害严重
• MRSA感染
–增加死亡风险1
–增加患病率2,3
死亡率相关性比较5： MRSA vs MSSA
–延长住院时间2,3
–增加住院费用1,2,4
研 究
0.1
注射用替考拉宁说明书
注射用替考拉宁说明书他格适(替考拉宁)治疗革兰阳性菌感染。
下面是小编整理的注射用替考拉宁说明书，欢迎阅读。
注射用替考拉宁商品介绍通用名：注射用替考拉宁生产厂家: 意大利安万特医药批准文号：注册证号H20120314药品规格：200mg*1瓶药品价格：￥359元注射用替考拉宁说明书【药品名称】通用名称：注射用替考拉宁商品名称：他格适英文名称：Targocid (Teicoplanin for Injection)汉语拼音：Zhusheyong Tikaolaning【主要成分】替考拉宁【性状】他格适为类白色冻干块状粉物和粉末。
【适应症】他格适可用于治疗各种严重的革兰阳性菌感染，包括不能用青霉素类和头孢菌素类其他抗生素者。
他格适可用于不能用青霉素类及头孢菌素类抗生素治疗或用上述抗生素治疗失败的严重葡萄球菌感染，或对其他抗生素耐药的葡萄球菌感染。
已证明替考拉宁对下列感染有效：皮肤和软组织感染，泌尿道感染，呼吸道感染，骨和关节感染，败血症，心内膜炎及持续不卧床腹膜透析相关性腹膜炎。
在骨科手术具有革兰阳性菌感染的高危因素时，他格适也可作预防用。
【用法用量】他格适既可以静脉注射也可以肌肉注射。
可以快速静脉注射，注射时间为3-5分种之间，或缓慢静脉滴注，滴注时间不少于30分钟。
一般每日给药一次，但第一天可以给药两次。
对敏感菌所致感染的大多数病人，给药后48-72小时会出现疗效反应，疗程长短则依据感染的类型、严重程度和病人的临床反应而定。
心内膜炎和骨髓炎的疗程则推荐为3周或更长时间。
严重感染和中性粒细胞减少的患儿，推荐剂量为10mg/kg，前三剂负荷剂量每12小时静脉注射一次，随后剂量为10mg/kg，静脉或肌肉注射，每天一次。
对中度感染，推荐剂量为10mg/kg，前三剂负荷剂量每12小时静脉注射一次，随后维持剂量为6mg/kg，静脉或肌肉注射，每天一次。
小于2个月的婴儿：婴儿第一天的推荐负荷剂量为16mg/kg，只用一剂，随后8mg/kg，每天一次。
DERSIMELAGON 产品说明书
488 Scientific AbstractsSystemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal modelsPOS0467 DERSIMELAGON, A NOVEL ORAL MELANOCORTIN1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OFSYSTEMIC SCLEROSISM. Kondo1, T. Suzuki1, Y. Kawano1, S. Kojima2, M. Miyashiro1, A. Matsumoto1, G. Kania3, P. Blyszczuk3, R. Ross4, P. Mulipa4, F. Del Galdo4, Y. Zhang5, J. H. W. Distler5. 1Mitsubishi T anabe Pharma Corporation, Research Unit/Immunology & Inflammation, Souyaku Innovative Research Division, Y okohama, Japan;2Mitsubishi T anabe Pharma Corporation, Discovery T echnology Laboratories, Souyaku Innovative Research Division, Y okohama, Japan;3University Hospital Zurich, University of Zurich, Center of Experimental Rheumatology, Department of Rheumatology, Schlieren, Switzerland;4University of Leeds, Leeds Instituteof Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, Leeds, United Kingdom;5Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Department of Internal Medicine 3—Rheumatology and Immunology, Erlangen, GermanyBackground: Activation of melanocortin 1 receptor (MC1R) is known to have broad anti-inflammatory and anti-fibrotic effects. The bleomycin (BLM)-induced skin fibrosis murine model is well-established for systemic sclerosis (SSc). α-mel-anocyte-stimulating hormone, an endogenous ligand of MC1R, inhibits skin fibro-sis and MC1R knock-out enhances skin fibrosis in this model. These pieces of evidence suggest that MC1R agonism has potential in the treatment of SSc. Objectives: Dersimelagon phosphate (MT-7117) is an investigational small molecule that is an orally administered, selective agonist for MC1R. The purpose of this study is to investigate the potential of MT-7117 as a therapeutic agent for SSc by evaluat-ing its efficacy and mechanism of action in complementary preclinical models. The expression and distribution of MC1R in the skin of SSc patients was investigated. Methods: The effects of MT-7117 on skin fibrosis and lung inflammation were eval-uated in BLM-induced SSc murine models that were optimized for prophylactic and therapeutic evaluation. Microarray-based gene expression analysis and serum pro-tein profiling were performed to investigate the mechanism of action of MT-7117 in the BLM-induced SSc models. The effect of MT-7117 on TGF-β-induced activation of human dermal fibroblasts was evaluated in vitro. Immunohistochemical analyses of MC1R expression in skin samples from SSc patients were performed. Results: Prophylactic treatment with MT-7117 (≥0.3 mg/kg/day p.o.) significantly inhibited the increase in collagen content of the skin, the serum level of sur-factant protein D, and the weight of the lungs from BLM-induced skin fibrosis and lung inflammation model. Therapeutic treatment with MT-7117 (≥3 mg/kg/ day p.o.) significantly suppressed skin thickening and the numbers of myofi-broblasts in pre-established BLM-induced skin fibrosis model. Gene array anal-ysis using the BLM-induced SSc model demonstrated changes in numerous categories related to macrophages, monocytes, and neutrophils, followed by endothelial cell-related categories after treatment with MT-7117. In the analy-sis that focused on biological functions, categories of inflammatory response, activation of antigen-presenting cells, angiogenesis, atherosclerosis, vascu-logenesis, and vaso-occlusion were suppressed by MT-7117. In the analysis that focused on molecular signaling pathways, triggering receptor expressed on myeloid cells-1, IL-6, and oncostatin M involved in inflammation, and perox-isome proliferator-activated receptor that is related to fibrosis were all affected by MT-7117. Serum protein profiling using BLM-induced SSc model revealed that multiple SSc-related biomarkers including P-selectin, osteoprotegerin, cys-tatin C, growth and differentiation factor-15 and S100A9 were suppressed by MT-7117. MT-7117 inhibited the activation of human dermal fibroblasts by sup-pressing TGF-β-induced ACTA2 (encoding α-smooth muscle actin) mRNA ele-vation in vitro. Immunohistochemical analyses showed that MC1R positivity was observed in 40 of 50 diffuse cutaneous SSc patients. MC1R was expressed by monocytes/macrophages, neutrophils, blood vessels (endothelial cells), fibro-blasts, and epidermis (keratinocytes) in the skin of SSc patients. Conclusion: MT-7117 demonstrates disease-modifying effects in preclinical mod-els of SSc. Investigations of its mechanism of action and target expression anal-yses indicate that MT-7117 exerts its positive effects by affecting the pathologies of inflammation, vascular dysfunction, and fibrosis through inflammatory cells, endothelial cells, and fibroblasts. In view of its potent beneficial impact on all these three main pathologies of SSc, MT-7117 is a potential therapeutic agent for the treatment of clinically challenging SSc, which has diverse and difficult to treat symp-toms. A phase 2 clinical trial investigating the efficacy and tolerability of MT-7117 in patients with early, progressive diffuse cutaneous SSc is currently in progress. Disclosure of Interests: Masahiro Kondo Employee of: Mitsubishi Tanabe Pharma Corporation, Tsuyoshi Suzuki Employee of: Mitsubishi Tanabe Pharma Corporation, Yuko Kawano Employee of: Mitsubishi Tanabe Pharma Corpora-tion, Shinji Kojima Employee of: Mitsubishi Tanabe Pharma Corporation, Masa-hiko Miyashiro Employee of: Mitsubishi Tanabe Pharma Corporation, Atsuhiro Matsumoto Employee of: Mitsubishi Tanabe Pharma Corporation, Gabriela Kania: None declared, Przemyslaw Blyszczuk: None declared, rebecca ross:None declared, Panji Mulipa: None declared, Francesco Del Galdo Grant/ research support from: Prof. F. Del Galdo received fees and research supportfrom Abbvie, AstraZeneca, Boehringer-Ingelheim, Capella, Chemomab, Kymab, Janssen and Mitsubishi-Tanabe., Yun Zhang: None declared, Jörg H.W. DistlerGrant/research support from: Prof. J.H.W. Distler received consulting fees, lec-ture fees, and/or honoraria from Actelion, Active Biotech, Anamar, ARXX, aTyr,Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, Sanofi-Aventis, RedX, RuiYi and UCB. J. H. W.Distler is stock owner of 4D Science and Scientific head of FibroCure.DOI: 10.1136/annrheumdis-2022-eular.29POS0468 EXTRACELLULAR VESICLES FROM SERUM OFMYOSITIS PATIENTS AS CIRCULATING BIOMARKERSAND DISEASE MEDIATORSS. Kivity1,2, H. Kravitz3, C. Cohen3, D. Margoulis3, M. Amar3, G. Kazimirsky3,D. Ozeri4, A. Dori5, C. Brodie3. 1Meir Medical Center, Rheumatology Unit, KefarSava, Israel;2T el Aviv University, Sackler faculty of Medicine, T el Aviv-Y afo, Israel;3Bar-Ilan University, The Mina and Everard Goodman Faculty of Life Sciences,Ramat Gan, Israel;4T el-HaShomer The Sheba Medical Center, ZabludowiczCenter for Autoimmune Disease, Ramat Gan, Israel;5T el-HaShomer The ShebaMedical Center, Department of Neurology, T alpiot Medical Leadership Program,Sackler Faculty of Medicine, T el Aviv University, Ramat Gan, IsraelBackground: Inflammatory myopathies (IM) are a heterogeneous group of disor-ders characterized by autoimmune inflammatory destruction of skeletal muscles.It is many times associated with lung, skin and joint involvement. Identifying bio-markers that can differentiate IM from other muscle disorders may elucidate the pathophysiology of IM, guide novel therapies, monitor disease activity/responseto treatments and predict prognosis. Exosomes are membrane-bound nanove-sicles with diameters of 30-150 nm that contain multiple proteins, nucleic acid,lipids and other molecules in a tissue- and cell-specific manner. Exosomes are secreted by a large variety of cells, play major roles in cell-cell interactions, andhave recently emerged as circulating biomarkers in a variety of pathological con-ditions, including several autoimmune diseases.Objectives: To characterize exosomes from serum of IM patients, analyze pro-tein expression and study their potential mediators of disease pathologies.Methods: Serum was collected from patients suffering from IM(n=5) and from patients suffering from Becker (BMD) and Duchenne (DMD) muscular dystro-phies (n=6). Exosomes were isolated by Exoquick precipitation and analyzedfor size distribution and by nanoparticle tracking analysis (NTA) and by Westernblot for exosome markers. The effects of the isolated EVs on human satellitecell proliferation and differentiation and macrophage activation were examined. Results: Exosomes from IM patients decreased human satellite cell proliferation (51%, P<0.01) and inhibited their myogenic differentiation as indicated by lower fusionindex (24% inhibition, P<0.01) and expression of myosin heavy chain (72% inhibi-tion, P<0.001). Similar results were obtained also with exosomes derived from DMDand BMD patients; however, their inhibitory effect were more pronounced on MyoG expression. T reatment of macrophages with exosomes from IM patients significantly increased the expression of IL-10 (3-fold, P<0.001), compared to exosomes of healthy controls and DMD patients. Another significant difference was in the expression of sig-naling molecules: Thus, exosomes from BMD patients increased the phosphorylationof Erk and p38, whereas a smaller effect was induced by IM exosomes.Conclusion: Exosomes from IM patients decrease satellite cell proliferationand myogenic differentiation compared to healthy exosomes. In addition, these exosomes increased the expression of IL-10 in macrophages. These effects areunique to exosomes of IM patients compared to muscular dystrophies. These promising results suggest that serum exosomes should be further investigatedas a novel biomarker with potential therapeutic implications.Disclosure of Interests: Shaye Kivity Speakers bureau: BI, Abbvie, Lilly, Pfizer, Janssen, Neopharm, Grant/research support from: Sobi, Haya Kravitz: None declared, Coral Cohen: None declared, Darya Margoulis: None declared, MosheAmar: None declared, Gila Kazimirsky: None declared, David Ozeri Speakers bureau: Neopharm, Consultant of: Abbvie, Amir Dori Grant/research supportfrom: Biogen, Chaya Brodie Grant/research support from: Biogen.DOI: 10.1136/annrheumdis-2022-eular.63POS0469 ENDOTHELIAL TO MESENCHYMAL TRANSITIONAND SENESCENCE ARE PART OF THE FIBROTICPATHOGENESIS IN SYSTEMIC SCLEROSISY. H. Chiu1,2, J. Spierings1, J. M. Van Laar1, J. De Vries-Bouwstra3, M. VanDijk4, R. Goldschmeding4. 1University Medical Center Utrecht, Departmentof Rheumatology and Clinical Immunology, Utrecht, Netherlands;2T ri-ServiceGeneral Hospital, Division of Rheumatology/Immunology/Allergy, T aipei, T aiwan, Republic of China;3Leiden University Medical Center, The Department of on December 24, 2023 by guest. Protected by copyright./ Ann Rheum Dis: first published as 10.1136/annrheumdis-2022-eular.29 on 23 May 2022. Downloaded from。
他格适
商品名：他格适®/targocid®英文名：Teicoplanin汉语拼音：ZHU SHE YONG TI KAO LA NING通用名：注射用替考拉宁【理化特性】本品主要成分及其化学名称为：替考拉宁性状：他格适为非肠道给药抗生素，具有强的杀菌活性。
可供静脉或肌肉注射，每天一次。
他格适的活性成分是替考拉宁，一种新型糖肽类抗生素。
对厌氧的及需氧的革兰阳性菌均有抗菌活性。
敏感菌有金黄色葡萄球菌和凝固酶阴性葡萄球菌（包括对甲氧西林敏感及耐药菌），链球菌，肠球菌，单核细胞增多性李司特菌，细球菌，JK组棒状杆菌和革兰阳性厌氧菌，后者包括难辨梭状芽孢杆菌和消化球菌。
其活性谱范围同万古霉素相似。
由于替考拉宁独特的作用机制，很少出现耐替考拉宁的菌株。
所以对青霉素类及头孢菌素类，大环内酯类，四环素和氯霉素，氨基糖苷类和利福平耐药的革兰阳性菌，仍对替考拉宁敏感。
替考拉宁静脉和肌肉注射后，广泛渗透入各组织。
缓慢随血浆而清除，半衰期约70-100小时；从肾脏排出。
口服他格适不能被吸收。
药物类别：多肽类及其它抗生素分子式：A2-2, C88H97C12N9O33。
【药理作用】他格适抑制细胞壁合成的途径与万古霉素一样，干扰肽聚糖中新的部分的合成过程。
他格适通过肽聚糖亚单位中的氨基酰-D-丙氨酰-D丙氨酸部分结合而起效应，这种结合将正常可被细菌细胞的延长和交叉一桥酸识别的部位“隐藏”起来。
这种结合抑制两个方面：形成细胞壁链的亚单位的生长或延长将新键连接到细胞壁的最终穿越一桥步骤。
因此，细胞壁的整合和牢固遭损坏，细胞生长停止，细胞最后死亡。
药代动力学：吸收：替考拉宁在口服时是不会被吸收的。
在肌注后的生物利用度为94%。
分布（血清浓度）：对人静注后其血清浓度显示出两相的分布（一相快速的分布紧接着是一相较慢的分布），其半衰期分别为0.3和3小时左右。
该相分布跟随一个缓慢的排泄，其半衰期为70-100小时。
单剂量：给予健康人静注3或6mg/kg，5分钟后，其血清浓度分别为53.4和111.8mg/L。
Magistra TAV 58 产品说明书
15 TAV 58EBRTABLE POS.CODE ITALIAN ENGLISH FRANÇAIS DEUTSCH MAGISTRA TAV. 581PABF800294FACCIATA EST.EBRA EXTERNAL FACE DEVANTURE EXTERNE AUSSENVORDERWANDMAGISTRA TAV. 581PABF800293FACCIATA EST.EBR EXTERNAL FACE DEVANTURE EXTERNE AUSSENVORDERWANDMAGISTRA TAV. 582GABF800110AS.CRUSCOTTO GBR CONTROL PANEL PANNEAU DE COMMANDE STIRNBRETTMAGISTRA TAV. 582GABF800110AS.CRUSCOTTO GBR CONTROL PANEL PANNEAU DE COMMANDE STIRNBRETTMAGISTRA TAV. T.UN.PIANTANE BRG SIDE CROSSBAR CROISILLON LATERAL QUERSTRÄNGENMAGISTRA TAV. T.UN.PIANTANE BRG SIDE CROSSBAR CROISILLON LATERAL QUERSTRÄNGENMAGISTRA TAV. 584RTBF900119V.M8X10 APPOG.VASCA BRE TANKE SUPPORT SUPPORT CUVE REGLERHALTERUNGMAGISTRA TAV. 584RTBF900119V.M8X10 APPOG.VASCA BRE TANKE SUPPORT SUPPORT CUVE REGLERHALTERUNGMAGISTRA TAV. 585PABF900226PIANTANA ANT.SX BRG FRONT LEFT SUPPORT COLONNE AVANT GAUCHE SÄULE VORNE LINKSMAGISTRA TAV. 585PABF900226PIANTANA ANT.SX BRG FRONT LEFT SUPPORT COLONNE AVANT GAUCHE SÄULE VORNE LINKSMAGISTRA TAV. 586GABF800108AS.BASAM.GBR ACC.BASE SOUBASSEMENT UNTERGESTELLMAGISTRA TAV. 586GABF800108AS.BASAM.GBR ACC.BASE SOUBASSEMENT UNTERGESTELLMAGISTRA TAV. 587PABF900247TRA.ANT.UN.PIANTANE BRE BACK CROSSBAR CROISILLON ANTÉRIEUR VORDERER QUERTRÄGER MAGISTRA TAV. 587PABF900247TRA.ANT.UN.PIANTANE BRE BACK CROSSBAR CROISILLON ANTÉRIEUR VORDERER QUERTRÄGER MAGISTRA TAV. 588PABF900220SUP.CENTRALE PERNO RIB.BRG CENTRAL SUPPORT SUPPORT CENTRAL MITTLERE HALTERUNGMAGISTRA TAV. 588PABF900220SUP.CENTRALE PERNO RIB.BRG CENTRAL SUPPORT SUPPORT CENTRAL MITTLERE HALTERUNGMAGISTRA TAV. 589PABF800290SUP.MOTORE BRGA MOTOR SUPPORT SUPPORT MOTEUR HALTERUNGMAGISTRA TAV. 5810PABF900225PIANTANA ANT.DX BRG FRONT RIGHT SUPPORT COLONNE AVANT DROITE SÄULE VORNE RECHTSMAGISTRA TAV. 5810PABF900225PIANTANA ANT.DX BRG FRONT RIGHT SUPPORT COLONNE AVANT DROITE SÄULE VORNE RECHTSMAGISTRA TAV. 5811PABF900331PIANTANA POST.SX BRG REAR LEFT SUPPORT COLONNE ARRIÈRE GAUCHE SÄULE HINTEN LINKSMAGISTRA TAV. 5811PABF900331PIANTANA POST.SX BRG REAR LEFT SUPPORT COLONNE ARRIÈRE GAUCHE SÄULE HINTEN LINKSMAGISTRA TAV. 5816RTBF900101CERN.FISSA ANT.VASCA BRG ZINC.FIXED BASIN HINGE CHARNIÈRE FIXE CUVE FESTES WANNENSCHARNIER MAGISTRA TAV. 5816RTBF900101CERN.FISSA ANT.VASCA BRG ZINC.FIXED BASIN HINGE CHARNIÈRE FIXE CUVE FESTES WANNENSCHARNIER MAGISTRA TAV. 5817RTBF900099PERNO CERN.ANT.VASCA BRG HINGE PIN TOURILLON CHARNIÈRE SCHARNIERZAPFENMAGISTRA TAV. 5817RTBF900099PERNO CERN.ANT.VASCA BRG HINGE PIN TOURILLON CHARNIÈRE SCHARNIERZAPFENMAGISTRA TAV. 5818RTBF900100CERN.MOBILE ANT.VASCA BRG ZINC MOBIL BASIN HINGE CHARNIÈRE MOBILE CUVE BEWEGLICHES WANNENSCHARNIER MAGISTRA TAV. 5818RTBF900100CERN.MOBILE ANT.VASCA BRG ZINC MOBIL BASIN HINGE CHARNIÈRE MOBILE CUVE BEWEGLICHES WANNENSCHARNIER MAGISTRA TAV. 5819PABF800286FIANCO SX GBR LEFT SIDE CÔTÉ GAUCHE LINKE SEITEMAGISTRA TAV. 5819PABF800286FIANCO SX GBR LEFT SIDE CÔTÉ GAUCHE LINKE SEITEMAGISTRA TAV. 5820RTBF800300VASCA EBR TANK CUVE WANNEMAGISTRA TAV. 5820RTBF800300VASCA EBR TANK CUVE WANNEMAGISTRA TAV. 5821GABF800106AS.COPERCHIO GBR COVER COUVERCLE TOPFDECKELMAGISTRA TAV. 5821GABF800106AS.COPERCHIO GBR COVER COUVERCLE TOPFDECKELMAGISTRA TAV. 5822RTCP800031*MANIGLIA COP.G100COVER HANDLE POIGNÉE DU COUVERCLE DECHEKGRIFFMAGISTRA TAV. 5822RTCP800031*MANIGLIA COP.G100COVER HANDLE POIGNÉE DU COUVERCLE DECHEKGRIFFMAGISTRA TAV. PLETA INOX COP.GBR COVER HINGE CHARNIÈRE COUVERCLE ABDECKUNGSSCHARNIER MAGISTRA TAV. PLETA INOX COP.GBR COVER HINGE CHARNIÈRE COUVERCLE ABDECKUNGSSCHARNIER MAGISTRA TAV. 5824RTCP800030*TERMINALE DX CERN.COP.G100HINGE RIGHT TERMINAL TERMINAL DROITE CHARNIÉRE RECHTER ENDVERSCHLUßMAGISTRA TAV. 5824RTCP800030*TERMINALE DX CERN.COP.G100HINGE RIGHT TERMINAL TERMINAL DROITE CHARNIÉRE RECHTER ENDVERSCHLUßMAGISTRA TAV. 5826RTCP800028*REGOLAT.MOLLA CERN.COP.G100COVE SPRING ADJ. DEVICE REGULATEUR RESSORT COUVERCLE FEDERREGLER ABDECKUNG MAGISTRA TAV. 5826RTCP800028*REGOLAT.MOLLA CERN.COP.G100COVE SPRING ADJ. DEVICE REGULATEUR RESSORT COUVERCLE FEDERREGLER ABDECKUNG MAGISTRA TAV. 5827RTBF800103MOLLA CERNIERA COP.BRG/GBR SPRIENG FOR COVER HINGE RÉSSORT POUR CHARNIÉRE SCHARNIERFEDERMAGISTRA TAV. 5827RTBF800103MOLLA CERNIERA COP.BRG/GBR SPRIENG FOR COVER HINGE RÉSSORT POUR CHARNIÉRE SCHARNIERFEDERMAGISTRA TAV. 5828RTCP800027*GUIDA MOLLA CERN.COP.G100HINGE SPRING GUIDE GUIDE POUR RÉSSORT CHARNIÉRE COUVER TÜRFEDERFÜHRUNGTABLE POS.CODE ITALIAN ENGLISH FRANÇAIS DEUTSCH MAGISTRA TAV. 5828RTCP800027*GUIDA MOLLA CERN.COP.G100HINGE SPRING GUIDE GUIDE POUR RÉSSORT CHARNIÉRE COUVER TÜRFEDERFÜHRUNG MAGISTRA TAV. 5829GACU800014AS.GRIGLIA CAM.G4SF SMALT.CHIMNEY GRILL GRILLE DE LA CHEMINÉE SCHORNSTEINROST MAGISTRA TAV. 5829GACU800014AS.GRIGLIA CAM.G4SF SMALT.CHIMNEY GRILL GRILLE DE LA CHEMINÉE SCHORNSTEINROST MAGISTRA TAV. 5830GABF800111AS.CAMINETTO SUP.GBR SUPERIOR CHIMNEY CHEMINÉE SUPERIEURE OBERER SCHORNSTEIN MAGISTRA TAV. 5830GABF800111AS.CAMINETTO SUP.GBR SUPERIOR CHIMNEY CHEMINÉE SUPERIEURE OBERER SCHORNSTEIN MAGISTRA TAV. 5831PABF800280POSTERIORE INOX GBR STAINLESS STEEL BACK PANEL PANNEAU POSTÉRIEURE INOX INOX-RÜCKWANDMAGISTRA TAV. 5831PABF800280POSTERIORE INOX GBR STAINLESS STEEL BACK PANEL PANNEAU POSTÉRIEURE INOX INOX-RÜCKWANDMAGISTRA TAV. 5832PABF900243PI.INF.INOX BRE LOWER PLAN PLAN INFERIEUR UNTERE EBENEMAGISTRA TAV. 5832PABF900243PI.INF.INOX BRE LOWER PLAN PLAN INFERIEUR UNTERE EBENEMAGISTRA TAV. 5833GABF800107AS.CONTORNO R/OLIO GBR OIL COLLECTION EDGE CONTOURÖLSAMMELRANDMAGISTRA TAV. 5833GABF800107AS.CONTORNO R/OLIO GBR OIL COLLECTION EDGE CONTOURÖLSAMMELRANDMAGISTRA TAV. 5834GABF800112AS.TRA.POST.UN.PIANTANE GBR REAR CROSSBAR CROISILLON POSTERIEURE HINTERE QUERTRÄGER MAGISTRA TAV. 5834GABF800112AS.TRA.POST.UN.PIANTANE GBR REAR CROSSBAR CROISILLON POSTERIEURE HINTERE QUERTRÄGER MAGISTRA TAV. 5835PABF900227PIANTANA POST.DX BRG REAR RIGHT SUPPORT COLONNA ARRIÉRE DROITE SÄULE HINTEN RECHTS MAGISTRA TAV. 5835PABF900227PIANTANA POST.DX BRG REAR RIGHT SUPPORT COLONNA ARRIÉRE DROITE SÄULE HINTEN RECHTS MAGISTRA TAV. 5836RTMIN00123SEEGER ESTERNO E10.SEEGER Ø 10SEEGER Ø 10SEEGER Ø 10MAGISTRA TAV. 5836RTMIN00123SEEGER ESTERNO E10.SEEGER Ø 10SEEGER Ø 10SEEGER Ø 10TAV 57EBRTABLE POS.CODE ITALIAN ENGLISH FRANÇAIS DEUTSCH MAGISTRA TAV. 571RTBF900104SUP.OSCILL.FORI/16 BRG LEN206OSCILLATING SUPPORT SUPPORT OSCILLANT GELENKLAGERMAGISTRA TAV. 571RTBF900104SUP.OSCILL.FORI/16 BRG LEN206OSCILLATING SUPPORT SUPPORT OSCILLANT GELENKLAGERMAGISTRA TAV. 571RTBF900104SUP.OSCILL.FORI/16 BRG LEN206OSCILLATING SUPPORT SUPPORT OSCILLANT GELENKLAGERMAGISTRA TAV. 571RTBF900104SUP.OSCILL.FORI/16 BRG LEN206OSCILLATING SUPPORT SUPPORT OSCILLANT GELENKLAGERMAGISTRA TAV. 572RTBF900106RIBALTATORE VASCA BRG ZINC.TANK TILTING DEVICE BASCULEUR BAC WANNENDIPPVORRICHTUNG MAGISTRA TAV. 572RTBF900106RIBALTATORE VASCA BRG ZINC.TANK TILTING DEVICE BASCULEUR BAC WANNENDIPPVORRICHTUNG MAGISTRA TAV. 572RTBF900106RIBALTATORE VASCA BRG ZINC.TANK TILTING DEVICE BASCULEUR BAC WANNENDIPPVORRICHTUNG MAGISTRA TAV. 572RTBF900106RIBALTATORE VASCA BRG ZINC.TANK TILTING DEVICE BASCULEUR BAC WANNENDIPPVORRICHTUNG MAGISTRA TAV. 573RTBF900110PROLUNGA RIBALT.BRG FILTING DEVICE EXTENSION RALLONGE BASCULEUR KIPPVORRICHTUNGSVERLÄNGERUNG MAGISTRA TAV. 573RTBF900110PROLUNGA RIBALT.BRG FILTING DEVICE EXTENSION RALLONGE BASCULEUR KIPPVORRICHTUNGSVERLÄNGERUNG MAGISTRA TAV. 573RTBF900110PROLUNGA RIBALT.BRG FILTING DEVICE EXTENSION RALLONGE BASCULEUR KIPPVORRICHTUNGSVERLÄNGERUNG MAGISTRA TAV. 573RTBF900110PROLUNGA RIBALT.BRG FILTING DEVICE EXTENSION RALLONGE BASCULEUR KIPPVORRICHTUNGSVERLÄNGERUNG MAGISTRA TAV. 574RTBF900096PERNO FIS.PROLUNGA RIB.BRG FILTING DEVICE PLUG PRISE BASCULEUR KIPPVORRICHTUNGSSTIFT MAGISTRA TAV. 574RTBF900096PERNO FIS.PROLUNGA RIB.BRG FILTING DEVICE PLUG PRISE BASCULEUR KIPPVORRICHTUNGSSTIFT MAGISTRA TAV. 574RTBF900096PERNO FIS.PROLUNGA RIB.BRG FILTING DEVICE PLUG PRISE BASCULEUR KIPPVORRICHTUNGSSTIFT MAGISTRA TAV. 574RTBF900096PERNO FIS.PROLUNGA RIB.BRG FILTING DEVICE PLUG PRISE BASCULEUR KIPPVORRICHTUNGSSTIFT MAGISTRA TAV. 575RTMIN00123SEEGER ESTERNO E10.SEEGER Ø 10SEEGER Ø 10SEEGER Ø 10MAGISTRA TAV. 575RTMIN00123SEEGER ESTERNO E10.SEEGER Ø 10SEEGER Ø 10SEEGER Ø 10MAGISTRA TAV. 575RTMIN00123SEEGER ESTERNO E10.SEEGER Ø 10SEEGER Ø 10SEEGER Ø 10MAGISTRA TAV. 575RTMIN00123SEEGER ESTERNO E10.SEEGER Ø 10SEEGER Ø 10SEEGER Ø 10MAGISTRA TAV. 576RTBF900102PERNO FIS.RIDUTTORE BRG ZINC.REDUCTION ATTACHMENT PIN TOURILLON FIXATION RÉDUCTEUR KIPPVORRICHTUNGMAGISTRA TAV. 576RTBF900102PERNO FIS.RIDUTTORE BRG ZINC.REDUCTION ATTACHMENT PIN TOURILLON FIXATION RÉDUCTEUR KIPPVORRICHTUNGMAGISTRA TAV. 576RTBF900102PERNO FIS.RIDUTTORE BRG ZINC.REDUCTION ATTACHMENT PIN TOURILLON FIXATION RÉDUCTEUR KIPPVORRICHTUNGMAGISTRA TAV. 576RTBF900102PERNO FIS.RIDUTTORE BRG ZINC.REDUCTION ATTACHMENT PIN TOURILLON FIXATION RÉDUCTEUR KIPPVORRICHTUNGMAGISTRA TAV. 577RTBF900109RIDUTTORE BRG/GBR REDUCTION UNIT RÉDUCTEUR UNTERSETZUNGSGETRIEBE MAGISTRA TAV. 577RTBF900109RIDUTTORE BRG/GBR REDUCTION UNIT RÉDUCTEUR UNTERSETZUNGSGETRIEBE MAGISTRA TAV. 577RTBF900109RIDUTTORE BRG/GBR REDUCTION UNIT RÉDUCTEUR UNTERSETZUNGSGETRIEBE MAGISTRA TAV. 577RTBF900109RIDUTTORE BRG/GBR REDUCTION UNIT RÉDUCTEUR UNTERSETZUNGSGETRIEBE MAGISTRA TAV. 578RTMIN00226CHIAVETTA INC.BRG/8X7X40 ACC.KEY 8X7X40CLAVETTE 8X7X40FEDER 8X7X40MAGISTRA TAV. 578RTMIN00226CHIAVETTA INC.BRG/8X7X40 ACC.KEY 8X7X40CLAVETTE 8X7X40FEDER 8X7X40MAGISTRA TAV. 578RTMIN00226CHIAVETTA INC.BRG/8X7X40 ACC.KEY 8X7X40CLAVETTE 8X7X40FEDER 8X7X40MAGISTRA TAV. 578RTMIN00226CHIAVETTA INC.BRG/8X7X40 ACC.KEY 8X7X40CLAVETTE 8X7X40FEDER 8X7X40MAGISTRA TAV. 579RTBF800093VOLANTINO GBR HANDWAL VOLANT HANDWELMAGISTRA TAV. 579RTBF800093VOLANTINO GBR HANDWAL VOLANT HANDWELMAGISTRA TAV. 5710RTBF900105BUSSOLA PROL.VOLANT.BRG FLYIMPELLER EXTENSION BUSHING FOURREAU ROLLONGE VOLANT HANDRADVERLÄNGERUNGSBUCHSE MAGISTRA TAV. 5710RTBF900105BUSSOLA PROL.VOLANT.BRG FLYIMPELLER EXTENSION BUSHING FOURREAU ROLLONGE VOLANT HANDRADVERLÄNGERUNGSBUCHSE MAGISTRA TAV. 5711RTMIN00250CHIAVETTA INC.BRGA/6X6X39 ACC.KEY 6X6X39CLAVETTE 6X6X39FEDER 6X6X39MAGISTRA TAV. 5711RTMIN00250CHIAVETTA INC.BRGA/6X6X39 ACC.KEY 6X6X39CLAVETTE 6X6X39FEDER 6X6X39MAGISTRA TAV. 5712RTBF900124PULEGGIA RIDUTT.BRGA D210/TZ REDUCTION UNIT PULLEY POULIE RÉDUTEUR RIEMENSCHEIBEMAGISTRA TAV. 5712RTBF900124PULEGGIA RIDUTT.BRGA D210/TZ REDUCTION UNIT PULLEY POULIE RÉDUTEUR RIEMENSCHEIBEMAGISTRA TAV. 5713GABF900121MANIGLIA SOCCORSO BRGA ZINC.B.EMERGENCY HANDLE POIGNÉE DE SECOURS NOT-GRIFFMAGISTRA TAV. 5713GABF900121MANIGLIA SOCCORSO BRGA ZINC.B.EMERGENCY HANDLE POIGNÉE DE SECOURS NOT-GRIFFMAGISTRA TAV. 5714RTBF900125CINGHIA TRAPEZ.BRGA T.Z36X915VBELT COURROI TRAPÉZOIDALE KEILRIEMENMAGISTRA TAV. 5715RTMIN00251*CHIAVETTA INC.BRGA/5X5X25 ACC KEY 5X5X25CLAVETT 5X5X25FEDER 5X5X25TABLE POS.CODE ITALIAN ENGLISH FRANÇAIS DEUTSCHMAGISTRA TAV. 5715RTMIN00251*CHIAVETTA INC.BRGA/5X5X25 ACC KEY 5X5X25CLAVETT 5X5X25FEDER 5X5X25MAGISTRA TAV. 5716RTBF900123PULEGGIA MOTORE BRGA D50/TZ MOTOR PULLEY POULIE MOTEUR MOTOR-RIEMENSCHEIBEMAGISTRA TAV. 5716RTBF900123PULEGGIA MOTORE BRGA D50/TZ MOTOR PULLEY POULIE MOTEUR MOTOR-RIEMENSCHEIBEMAGISTRA TAV. 5717RTCU800156*CONDENS.MOT.450V/8MF MOTOR GUARD PROTECTION MOTEUR MOTORSCHUTZMAGISTRA TAV. 5717RTCU800156*CONDENS.MOT.450V/8MF MOTOR GUARD PROTECTION MOTEUR MOTORSCHUTZMAGISTRA TAV. 5718RTBF900122MOTORE+COND.SOLL.VASCA BRGA TANK TILTING MOTOR MOTEUR RELEVAGE BAC WANNENHEBEMOTORMAGISTRA TAV. 5718RTBF900122MOTORE+COND.SOLL.VASCA BRGA TANK TILTING MOTOR MOTEUR RELEVAGE BAC WANNENHEBEMOTORMAGISTRA TAV. 5719RTBF800123PULSANTE GBRA ZB2BA26PUSH BUTTON BOUTON DRUCKKNOPFMAGISTRA TAV. 5719RTBF800123PULSANTE GBRA ZB2BA26PUSH BUTTON BOUTON DRUCKKNOPFMAGISTRA TAV. 5720PABF900346SQ.FIS.PULSANTI BRGA BRACKET FOR PUSH BOTTON EGUERRE FIXATION BOUTONS WINKELEISENMAGISTRA TAV. 5720PABF900346SQ.FIS.PULSANTI BRGA BRACKET FOR PUSH BOTTON EGUERRE FIXATION BOUTONS WINKELEISENMAGISTRA TAV. 5721RTBF800125CONTATTI PULS.GBRA ZB2BZ105PUSH BUTTON CONTACT CONTACTS BOUTONS DRUCKKNOPFKONTAKTEMAGISTRA TAV. 5721RTBF800125CONTATTI PULS.GBRA ZB2BZ105PUSH BUTTON CONTACT CONTACTS BOUTONS DRUCKKNOPFKONTAKTEMAGISTRA TAV. 5722PABF900347PROTEZ.PULSANTI BRGA PUSHBOTTON GUARD PROTECTION BOUTONS POUSSOIRS SCHUTZVORRICHTUNGMAGISTRA TAV. 5722PABF900347PROTEZ.PULSANTI BRGA PUSHBOTTON GUARD PROTECTION BOUTONS POUSSOIRS SCHUTZVORRICHTUNGMAGISTRA TAV. 5723PABF900353FLANGIA FIS.PUL.RIDUTTORE BRGA PULLEY ATTACHMENT FLANGE BRIDE FIXATION POULIE BEFESTIGUNGSFLANSCH FÜR RIEMENSCHEIBE MAGISTRA TAV. 5723PABF900353FLANGIA FIS.PUL.RIDUTTORE BRGA PULLEY ATTACHMENT FLANGE BRIDE FIXATION POULIE BEFESTIGUNGSFLANSCH FÜR RIEMENSCHEIBETAV 59EBRTABLE POS.CODE ITALIAN ENGLISH FRANÇAIS DEUTSCHMAGISTRA TAV. 591RTCP800018RUB.ACQ.G100 17CR905M WATER TAP ROBINET DE L'EAU WASSERHAHNMAGISTRA TAV. 591RTCP800018RUB.ACQ.G100 17CR905M WATER TAP ROBINET DE L'EAU WASSERHAHNMAGISTRA TAV. 592RTBF800126NIPLES COMP.CIL/F/D10 01141021NIPLES FOR PIPE Ø 10NIPLES POUR TUYAU Ø 10NIPPEL FÜR SCHLAUCH Ø 10MAGISTRA TAV. 592RTBF800126NIPLES COMP.CIL/F/D10 01141021NIPLES FOR PIPE Ø 10NIPLES POUR TUYAU Ø 10NIPPEL FÜR SCHLAUCH Ø 10MAGISTRA TAV. 593PABF900131SQ.FIS.RESIST.FT2E ELEMENT FIXING BRACKET EGUERRE DE FIXAGE POUR RÉSISTANCE WIDERSTANDSBEFESTIGUNGSWINKEL MAGISTRA TAV. 593PABF900131SQ.FIS.RESIST.FT2E ELEMENT FIXING BRACKET EGUERRE DE FIXAGE POUR RÉSISTANCE WIDERSTANDSBEFESTIGUNGSWINKEL MAGISTRA TAV. 594PABF900202TU.AL.EROG.ACQ.V.BRG TANK FILLING PIPE TUYAU REMPLISSAGE BAC WANNENFÜLLROHRMAGISTRA TAV. 594PABF900202TU.AL.EROG.ACQ.V.BRG TANK FILLING PIPE TUYAU REMPLISSAGE BAC WANNENFÜLLROHRMAGISTRA TAV. 595PABF800292TU.AL.RUB.ACQ.GBR WATER FEEDING PIPE TUYAU DISTRIBUTION EAU HAHNVERSORGUNGSROHRMAGISTRA TAV. 595PABF800292TU.AL.RUB.ACQ.GBR WATER FEEDING PIPE TUYAU DISTRIBUTION EAU HAHNVERSORGUNGSROHRMAGISTRA TAV. 596GABF800035AS.ATT.ACQUA GBM90/GBR WATER CONNECTION ATTAQUE DE L'EAU WASSERANSCHLUSSMAGISTRA TAV. 596GABF800035AS.ATT.ACQUA GBM90/GBR WATER CONNECTION ATTAQUE DE L'EAU WASSERANSCHLUSSMAGISTRA TAV. 597RTCU900012BICONO D.10DOUBLE CONE D.10BICONE D.10DOPPELKONUS D.10MAGISTRA TAV. 597RTCU900012BICONO D.10DOUBLE CONE D.10BICONE D.10DOPPELKONUS D.10MAGISTRA TAV. 598RTCU900013CALOTTA D.10NUT ECROU MUTTERMAGISTRA TAV. 598RTCU900013CALOTTA D.10NUT ECROU MUTTERMAGISTRA TAV. 599RTBF800041EROGATORE ACQ.GC45 3/8"C44MB09WATER DISTRIBUTOR DISTRIBUTION POUR L'EAU WASSERVERSORGERMAGISTRA TAV. 599RTBF800041EROGATORE ACQ.GC45 3/8"C44MB09WATER DISTRIBUTOR DISTRIBUTION POUR L'EAU WASSERVERSORGERMAGISTRA TAV. 5910RTBF800026R.BRE 1.5KW230OVER HEATING ELECT. 1500W 240V.RÉSISTNCE ELECTRIQUE 1500W 240V.ELEKT. WIDERSTÄNDE 1500W 240V. MAGISTRA TAV. 5910RTBF800026R.BRE 1.5KW230OVER HEATING ELECT. 1500W 240V.RÉSISTNCE ELECTRIQUE 1500W 240V.ELEKT. WIDERSTÄNDE 1500W 240V. MAGISTRA TAV. 5911PABF900246CONT.INT.IS.RES.BRE EL. RESISTOR INSULATING CONTAINER BOÎTIER ISOLANT RÉSISTANCES EL.ISOLIERMITTELBEHÄLTER EL. WIDERSTÄNDE MAGISTRA TAV. 5911PABF900246CONT.INT.IS.RES.BRE EL. RESISTOR INSULATING CONTAINER BOÎTIER ISOLANT RÉSISTANCES EL.ISOLIERMITTELBEHÄLTER EL. WIDERSTÄNDE MAGISTRA TAV. 5912MPIS000003IS.INSULFRAX/1,26X1,10X9SP WATER FEEDING PIPE TUYAU DISTRIBUTION EAU HAHNVERSORGUNGSROHRMAGISTRA TAV. 5912MPIS000003IS.INSULFRAX/1,26X1,10X9SP WATER FEEDING PIPE TUYAU DISTRIBUTION EAU HAHNVERSORGUNGSROHRMAGISTRA TAV. 5913PABF900244CONT.EST.IS.RES.BRE EXTERIOR CONTAINER FOR INSULATION BOÎTIER EXTERNE POUR ISOLANT EXTERNER ISOLIERMITTELBEHÄLTER MAGISTRA TAV. 5913PABF900244CONT.EST.IS.RES.BRE EXTERIOR CONTAINER FOR INSULATION BOÎTIER EXTERNE POUR ISOLANT EXTERNER ISOLIERMITTELBEHÄLTER MAGISTRA TAV. 5914PABF900248PIASTRINA FORO CONT.EST.IS.BRE HOLE COVER PLATE PLAQUETTE BOUCHE-TROU LOCHABDECKUNGMAGISTRA TAV. 5914PABF900248PIASTRINA FORO CONT.EST.IS.BRE HOLE COVER PLATE PLAQUETTE BOUCHE-TROU LOCHABDECKUNGMAGISTRA TAV. 5915PABF900245PROTEZ.MORS.RES.BRE EL. RESISTOR TERMINAL STRIP GNARD PROTECTION BORNIER RÉSISTANCES SCHUTZVORRICHTUNG KLEMMBRETTER MAGISTRA TAV. 5915PABF900245PROTEZ.MORS.RES.BRE EL. RESISTOR TERMINAL STRIP GNARD PROTECTION BORNIER RÉSISTANCES SCHUTZVORRICHTUNG KLEMMBRETTER MAGISTRA TAV. 5916PABF900230SCATOLA P/COMANDI BRG CONTROL BOX BOÎTER PORTE-COMMANDES STEUERUNGSKASTENMAGISTRA TAV. 5916PABF900230SCATOLA P/COMANDI BRG CONTROL BOX BOÎTER PORTE-COMMANDES STEUERUNGSKASTENMAGISTRA TAV. 5917PABF900045*PIANTANA SX FACC.BM4G WATER FEEDING PIPE TUYAU DISTRIBUTION EAU HAHNVERSORGUNGSROHRMAGISTRA TAV. 5917PABF900045*PIANTANA SX FACC.BM4G WATER FEEDING PIPE TUYAU DISTRIBUTION EAU HAHNVERSORGUNGSROHRMAGISTRA TAV. 5918GABF900117AS.COPERCHIO SCAT.P/COM.BRG BOX COVER COUVERCLE BOÎTER KASTENDECKELMAGISTRA TAV. 5918GABF900117AS.COPERCHIO SCAT.P/COM.BRG BOX COVER COUVERCLE BOÎTER KASTENDECKELMAGISTRA TAV. 5919RTCU700212COMM.BM2E 4922015705 C COMMUTATOR COMMUTATEUR KOMMUTATORMAGISTRA TAV. 5919RTCU700212COMM.BM2E 4922015705 C COMMUTATOR COMMUTATEUR KOMMUTATORMAGISTRA TAV. 5920RTCU900290LAMP.SP.VERDE/250V/TBF013.SF6GREEN WARNING LAMP LAMPE TEMOIN VERTE GRÜNE KONTROLLEUCHTEMAGISTRA TAV. 5920RTCU900290LAMP.SP.VERDE/250V/TBF013.SF6GREEN WARNING LAMP LAMPE TEMOIN VERTE GRÜNE KONTROLLEUCHTEMAGISTRA TAV. .EF90 0+1 NERO COMMUTATOR KNOB BOUTON DU COMMUTATEUR KOMMUTATORKUGELGRIFFMAGISTRA TAV. .EF90 0+1 NERO COMMUTATOR KNOB BOUTON DU COMMUTATEUR KOMMUTATORKUGELGRIFFMAGISTRA TAV. 5922RTCU900072LAMP.SP.GIALLA/250V/TBF013.SF6YELLOW WARNING LAMP LAMPE TÉMOIN JAUNE GELBE KONTROLLEUCHTEMAGISTRA TAV. 5923RTCU700085T.E.C4EF70 5519062802THERMOSTAT THERMOSTAT THERMOSTATTABLE POS.CODE ITALIAN ENGLISH FRANÇAIS DEUTSCH MAGISTRA TAV. 5923RTCU700085T.E.C4EF70 5519062802THERMOSTAT THERMOSTAT THERMOSTATMAGISTRA TAV. 5924RTBF800085MANOP.TERM.E.GBR 0+8 ROSSO THERMOSTAT KNOB BOUTON DU THERMOSTAT THERMOSTATKUGELGRIFF MAGISTRA TAV. 5924RTBF800085MANOP.TERM.E.GBR 0+8 ROSSO THERMOSTAT KNOB BOUTON DU THERMOSTAT THERMOSTATKUGELGRIFF MAGISTRA TAV. 5925RTBF800192T.L.EBR/T420 5532582804RELAY RELAIS RELAISMAGISTRA TAV. 5925RTBF800192T.L.EBR/T420 5532582804RELAY RELAIS RELAISMAGISTRA TAV. 5926RTBF800153*RELAIS EBR SN20CXAC230V1A1B RELAY RELAIS RELAISMAGISTRA TAV. 5926RTBF800153*RELAIS EBR SN20CXAC230V1A1B RELAY RELAIS RELAISMAGISTRA TAV. 5927RTBF800149*MORSETTIERA EBR+SIMB/1-12 C TERMINAL BLOC 12 POLE GROUPE DE CONNECTION DE CABLES KLEMMENBREIT 12 POLIG MAGISTRA TAV. 5927RTBF800149*MORSETTIERA EBR+SIMB/1-12 C TERMINAL BLOC 12 POLE GROUPE DE CONNECTION DE CABLES KLEMMENBREIT 12 POLIG MAGISTRA TAV. 5928RTBF800138F/CAVOPG21 53015050+D5*******C CABLE CLAMB Ø 9FIXE-CABLE Ø 9KABELHALTER Ø 9 MAGISTRA TAV. 5928RTBF800138F/CAVOPG21 53015050+D5*******C CABLE CLAMB Ø 9FIXE-CABLE Ø 9KABELHALTER Ø 9 MAGISTRA TAV. 5929RTCU700102PASSACAVO D9+DADO GEW52002CABLE-GUIDE Ø 9PASSE-CABLE Ø 9KABELRINNE Ø 9MAGISTRA TAV. 5929RTCU700102PASSACAVO D9+DADO GEW52002CABLE-GUIDE Ø 9PASSE-CABLE Ø 9KABELRINNE Ø 9MAGISTRA TAV. 5930RTCU700103PASSACAVO PG21+DADO GW52006CABLE GUIDE PASSE-CABLE KABELRINNEMAGISTRA TAV. 5930RTCU700103PASSACAVO PG21+DADO GW52006CABLE GUIDE PASSE-CABLE KABELRINNEMAGISTRA TAV. 5931RTBF800113MICROINT.SOLL.VASCA GBR C7DZN MICROSWITCH MICRO-INTERRUPTEUR MIKRO SCHALTER MAGISTRA TAV. 5931RTBF800113MICROINT.SOLL.VASCA GBR C7DZN MICROSWITCH MICRO-INTERRUPTEUR MIKRO SCHALTER。
Viltepso (viltolarsen) 产品说明书
Viltepso® (viltolarsen)(Intravenous)Document Number: IC-0562 Last Review Date: 08/01/2022Date of Origin: 09/01/2020Dates Reviewed: 09/2020, 01/2021, 04/2021, 08/2021, 08/2022I.Length of AuthorizationCoverage will be for 6 months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [NDC Unit]:•Viltepso 250 mg/5 mL single-dose vial: 36 vials per 7 daysB.Max Units (per dose and over time) [HCPCS Unit]:•920 billable units (9200 mg) every 7 daysIII.Initial Approval CriteriaCoverage is provided in the following conditions:Universal Criteria 1,5•Patient is not on concomitant therapy with other DMD-directed antisense oligonucleotides(e.g., eteplirsen, golodirsen, casimersen, etc.); AND•Patient does not have symptomatic cardiomyopathy; AND•Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio (UPCR) are measured prior to starting therapy and periodically during treatment; AND Duchenne Muscular Dystrophy (DMD) † Ф1-8•Patient has a confirmed mutation of the DMD gene that is amenable to exon 53 skipping;AND•Patient has been on a stable dose of corticosteroids, unless contraindicated or intolerance, for at least 3 months; AND•Patient retains meaningful voluntary motor function (e.g., patient is able to speak, manipulate objects using upper extremities, ambulate, etc.); AND•Patient is receiving physical and/or occupational therapy; AND•Baseline documentation of one or more of the following:o Dystrophin levelo Timed function tests (e.g., 6-minute walk test [6MWT], time to stand [TTSTAND], time to run/walk 10 meters [TTRW], time to climb 4 stairs [TTCLIMB], etc.)o Upper limb function (ULM) testo North Star Ambulatory Assessment (NSAA) scoreo Forced Vital Capacity (FVC) percent predicted† FDA-labeled indication(s); ‡ Compendia recommended indication(s); Ф Orphan DrugIV.Renewal Criteria 1,5,6Coverage may be renewed based upon the following criteria:•Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), etc. identified in section III; AND•Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: kidney toxicity (e.g., fatal glomerulonephritis, persistent increase in serum cystatin C,proteinuria, etc.), etc.; AND•Patient has responded to therapy compared to pretreatment baseline in one or more of the following (not all-inclusive):o Increase in dystrophin levelo Improvement in quality of lifeo Stability, improvement, or slowed rate of decline in one or more of the following: ▪Timed function tests (e.g., 6-minute walk test [6MWT], time to stand [TTSTAND], time to run/walk 10 meters [TTRW], time to climb 4 stairs [TTCLIMB], etc.) ▪Upper limb function (ULM) test▪North Star Ambulatory Assessment (NSAA) score▪Forced Vital Capacity (FVC) percent predictedV.Dosage/Administration 1Duchenne MuscularAdminister 80 mg/kg intravenously once weekly.DystrophyVI.Billing Code/Availability InformationHCPCS Code:•J1427 – Injection, viltolarsen, 10 mg; 1 billable unit = 10 mgNDC:•Viltepso 250 mg/5 mL single-dose vial: 73292-0011-xxVII.References1.Viltepso [package insert]. Paramus, NJ; NS Pharma, Inc.; March 2021. Accessed June 2022.2.Topaloglu H, Gloss D, Moxley RT 3rd, et al. Practice guideline update summary:Corticosteroid treatment of Duchenne muscular dystrophy: Report of the GuidelineDevelopment Subcommittee of the American Academy of Neurology. Neurology. 2016 Jul12;87(2):238.3.Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchennemuscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.Lancet Neurol; 2010 Jan; 9(1):77‑93.4.Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchennemuscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol; 2010Jan; 9(2):177-189.5.Clemens PR, Rao VK, Connolly AM, et al; CINRG DNHS Investigators. Safety, Tolerability,and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon53 Skipping: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2020 May 26. doi:10.1001/jamaneurol.2020.1264. [Avail at:https:///pmc/articles/PMC7251505/]6.Bushby K, Connor E. Clinical outcome measures for trials in Duchenne musculardystrophy: report from International Working Group meetings. Clin Investig (Lond).2011;1(9):1217-12357.Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchennemuscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, andgastrointestinal and nutritional management. Lancet Neurol 2018; 17:251.8.Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchennemuscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedicmanagement. Lancet Neurol 2018; 17:347.Appendix 1 – Covered Diagnosis CodesG71.01 Duchenne or Becker muscular dystrophyAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National CoverageDetermination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https:///medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/AJurisdiction Applicable State/US Territory ContractorE (1) CA, HI, NV, AS, GU, CNMI Noridian Healthcare Solutions, LLCF (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Noridian Healthcare Solutions, LLC5 KS, NE, IA, MO Wisconsin Physicians Service Insurance Corp (WPS)6 MN, WI, IL National Government Services, Inc. (NGS)H (4 & 7) LA, AR, MS, TX, OK, CO, NM Novitas Solutions, Inc.8 MI, IN Wisconsin Physicians Service Insurance Corp (WPS) N (9) FL, PR, VI First Coast Service Options, Inc.J (10) TN, GA, AL Palmetto GBA, LLCM (11) NC, SC, WV, VA (excluding below) Palmetto GBA, LLCNovitas Solutions, Inc.L (12) DE, MD, PA, NJ, DC (includes Arlington &Fairfax counties and the city of Alexandria in VA)K (13 & 14) NY, CT, MA, RI, VT, ME, NH National Government Services, Inc. (NGS)15 KY, OH CGS Administrators, LLC。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
他格适说明书
【批准文号】
注册证号 H20040293
【中文名称】
注射用替考拉宁
【产品英文名称】
【生产企业】
【功效主治】
耐青霉素、头孢菌素菌及青霉素过敏的革兰阳性菌感染。
【化学成分】
替考拉宁
【药理作用】
本品为与万古霉素类似的新糖肽抗生素，其抗菌谱及抗菌活性与万古霉
素相似。
对金葡菌的作用比万古霉素更强，不良反应更少。
本品对革兰
阳性菌如葡萄球菌、链球菌、肠球菌和大多厌氧性阳性菌敏感。
药效学
替考拉宁为一种新型糖肽类非肠道给药抗生素，具有强的杀菌活性。
可
供每天一次静脉或肌肉注射。
本药抑制细胞壁合成的途径与万古霉素一
样，干扰肽聚糖中新的部分的合成过程。
本药通过与肽聚糖亚单位中的
氨基酰-D-丙氨酰-D-丙氨酸部分结合而起效应，这种结合将正常可被细
菌细胞延长和交叉一桥酸识别的部位隐藏起来。
这种结合抑制两个方
面：形成细胞壁链的亚单位的生长或延长将新链接到细胞壁的最终穿越一桥步骤。
因此，细胞壁的整合和牢固遭损坏，细胞生长停止，细胞最
后死亡。
由于替考拉宁独特的作用机制，很少出现耐替考拉宁的菌株。
所以对青霉素类及头孢菌素类，大环内酯类、四环素和氯霉素，氨基糖
苷类和利福平耐药的革兰氏阳性菌，仍对替考拉宁敏感。
药动学吸
收：替考拉宁口服不吸收，肌注后的生物利用度为94%。
分布(血清浓
度)：对人静注后其血清浓度显示出两相的分布(一相快速的分布紧接着
是一相较慢的分布)，其半衰期分别为0.3和3小时左右。
该相分布跟随一个缓慢的排泄，其半衰期为70-100小时。
【药物相互作用】
临床实践中，本药常与其他类药物同时使用，包括其他抗生素、降压
药、麻醉剂、心脏病药、降糖药等，但未发现有不良的交叉反应。
【不良反应】
可引起注射处持久的疼痛。
亦具有耳毒性。
人们对本药耐受性良好，不
良反应一般轻微且短暂，很少需要中断治疗，严重不良反应罕见，已报
道主要有以下不良反应：局部反应：红斑、局部疼痛、血栓性静脉
炎。
变态反应：皮疹、瘙痒、发热、支气管痉挛、过敏反应。
胃肠道症状：恶心、呕吐、腹泻。
血液学：嗜酸粒细胞增多、白细胞减少、中
粒性细胞减少、血小板减少、血小板增多。
肝功能：血清转氨酶和/或
血清碱性磷酸酶增高。
肾功能：血清肌酐短暂升高。
中枢神经系统：
头晕、头痛。
其他虽已报道，但尚未明确与本药是否有关的不良反应
有：轻度听力下降，耳鸣和前庭功能紊乱。
【禁忌症】
对替考拉宁有过敏史者不可使用注射用替考拉宁。
【产品规格】
0.2g × 1
【用法用量】
静脉注射或滴注：成人，每日6mg～7mg/kg，开始2次/日，后改为1次/日。
肾功能正常的成人和老年人：矫形手术预防感染：麻醉诱导期单剂量静脉注射400 mg。
中度感染，如皮肤和软组织感染、泌尿系统感
染、呼吸道感染：负荷量：第一天400 mg，静脉注射1次。
维持
量：静脉或肌肉注射200 mg，每日1次。
严重感染，如骨和关节感
染、败血症、心内膜炎：负荷量：静脉注射400 mg，每12小时给药1次，连续3次。
维持量：静脉或肌肉注射400 mg，每日1次。
某些临
床情况，如严重烧伤感染或金黄色葡萄球菌心内膜炎病人，替考拉宁维
持量可能需要达到12 mg/kg。
儿童用药： 2月以上儿童革兰氏阳性菌
感染：严重感染和中性粒细胞减少的患儿，推荐剂量为10 mg/kg，前
三剂量每12小时静脉注射一次，随后剂量为10 mg/kg，静脉或肌肉注
射，每天1次。
对中度感染，推荐剂量为10 mg/kg，前三剂量每12小
时静脉注射1次，随后剂量为6 mg/kg，静脉或肌肉注射，每天1次。
新生儿：负荷量为第一天16 mg/kg，只用一剂，随后几天保持8
mg/kg，每天1次，静脉滴注时间不少于30分钟。
肾功能不全的成人和
老年人：肾功能受损患者，前3天仍然按常规剂量，第4天开始根据
血药浓度的测定结果调节治疗用量。
疗程第4天的用量：轻度肾功能不全者(肌酐清除率在40-60 mL/分)，剂量减半，方法是按常规剂量，隔
天1次 ;或剂量减半，每天1 次。
严重肾功能不全(肌酐清除率少于40 mL/分或血液透析者)，剂量为常规剂量的三分之一。
按常规剂量给药，
每三天1次 ;或按常规剂量三分之一给药，每天1次。
本品不能被血透
清除。
持续不卧床腹膜透析者：发热病人，第一次负荷剂量400 mg静
脉给药，然后推荐在第1周每袋透析液袋中按20 mg/L的剂量给药，第
3周仅在夜间的透析液袋内按20 mg/L的剂量给药。
本品200 mg及400 mg标准剂量分别相当于3 mg/kg及6 mg/kg平均剂量，如病人体重超过
85 kg，建议用相同治疗方案按公斤体重给药：中度感染为3 mg/kg，
严重感染为 6 mg/kg。
本药可以静脉注射也可以肌肉注射，快速静脉注
射时间不少于1分钟，缓慢静脉滴注时间不少于30分钟。
一般每日给药1次，但第一天可以给药2次。
对敏感菌所致感染的大多数病人，给药
后48-72小时会出现疗效反应，疗程长短则依据感染的类型、严重程度
和病人的临床反应而定。
心内膜炎和骨髓炎的疗程则推荐为3周或更长
时间。
【贮藏方法】
【注意事项】
对替考拉宁有过敏史者禁用。
妊娠及哺乳期妇女、小儿、严重肾功能不
全患者慎用。
一般腹膜透析和血液透析不影响本品的排出。
本药与万古
霉素可能有交叉过敏反应，故对万古霉素过敏者慎用，但用万古霉素曾
发生"红人综合征"者非本品禁忌症。
以前曾报告过用替考拉宁引起血小
板减少，特别是那些给药量高于常规用药量者，建议治疗期间进行血液
检查两次，并进行肝功能和肾功能的检测。
下述情况需监测肾功能和听
力：肾功能不全者长期用本药治疗，以及用本品期间同时和相继使用
可能有听神经毒性和/或肾毒性的其他药物，如氨基糖苷类，多粘菌素，二性霉素B，环孢菌素，顺铂，呋塞米和依他尼酸。
然而，上述药物与
本药联合应用时，并未证实有协同毒性。
监测替考拉宁血药浓度可使治
疗更完善，治疗严重感染时，本品血药浓度不应小于10 mg/L。
孕妇和
哺乳期间用药：虽然动物生殖实验并未显示本药有致畸作用，除非认为虽有危险仍非用不可，本药不应用于已确证妊娠或可能妊娠的妇女。
目
前尚无资料证实本药由乳汁排出或进入胎盘。